Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort pMDI dose-comparison study in COPD
2004-001183-41Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide and formoterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by AstraZeneca. Primary endpoints: Pre-dose FEV1 and 1 hour post-dose FEV1. Started Jan 2005; status: completed.
02
Drugs
budesonideformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2004-001183-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001183-41.